A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

NCT03165721 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

NIH

Sponsor class

Stopped Study closed to enrollment due to low accrual.

Conditions

Paraganglioma
Gastrointestinal Stromal Tumors
Carcinoma, Renal Cell
Renal Neoplasms
Pheochromocytoma

Interventions

DRUG: SGI-110 (guadecitabine)

Sponsor

National Cancer Institute (NCI)